ZD4054
ZD4054
ZD4054 (/zɛd fɔːr oʊ faɪv fɔːr/), also known as Zibotentan, is a specific endothelin receptor antagonist that was under development for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Etymology
The name ZD4054 is a systematic code assigned by the developing company, AstraZeneca. The prefix 'ZD' is commonly used in the naming of drugs developed by this company. The numbers '4054' do not have a known specific meaning.
Mechanism of Action
ZD4054 works by blocking the endothelin-1 receptors (ET_A). Endothelin-1 is a potent vasoconstrictor and has been implicated in the progression of cancer. By blocking these receptors, ZD4054 inhibits the action of endothelin-1, potentially slowing the growth and spread of cancer cells.
Clinical Trials
ZD4054 underwent Phase II and III clinical trials for the treatment of mCRPC. However, the drug did not meet its primary endpoint of improving overall survival in patients with mCRPC and development was discontinued.
Related Terms
- Endothelin receptor antagonist
- Metastatic
- Castration-resistant prostate cancer
- Clinical trials
- AstraZeneca
External links
- Medical encyclopedia article on ZD4054
- Wikipedia's article - ZD4054
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski